TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
| Life Sciences Tools & Services Industry | Healthcare Sector | Serge Saxonov CEO | LSE Exchange | 88025U109 CUSIP |
| US Country | 1,178 Employees | - Last Dividend | 17 Jul 2006 Last Split | 12 Sep 2019 IPO Date |
10x Genomics, Inc. is a prominent life science technology company known for its innovative development and commercialization of instruments, consumables, and software aimed at analyzing biological systems. The company's footprint extends across the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific regions, catering to a diverse clientele that includes academic, government, biopharmaceutical, biotechnology, and other institutions. Originally named 10X Technologies, Inc., it underwent a rebranding to 10x Genomics, Inc. in November 2014. Since its inception in 2012, 10x Genomics has established its headquarters in Pleasanton, California, positioning itself as a leader in the field of genomics and cellular analysis.